Reasons and Factors Contributing to Chinese Patients’ Preference for Ustekinumab in Crohn’s Disease: A Multicenter Cross-Sectional Study

Background and Aims: Ustekinumab (UST) was approved in China for treating moderate-to-severe Crohn’s disease (CD) in 2020. We aimed to identify the reasons and possible contributing factors for UST preference in Chinese patients with CD. Methods: We conducted a multicenter cross-sectional survey amo...

Descripción completa

Detalles Bibliográficos
Autores principales: Yao, Lingya, Zhu, Xiao, Shao, Bule, Liu, Rongbei, Li, Zhilun, Wu, Lexi, Chen, Jin, Cao, Qian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8651007/
https://www.ncbi.nlm.nih.gov/pubmed/34887751
http://dx.doi.org/10.3389/fphar.2021.736149

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8651007/
https://www.ncbi.nlm.nih.gov/pubmed/34887751
http://dx.doi.org/10.3389/fphar.2021.736149

Ejemplares similares